{"result": "(\"entity\"<|>MSUD<|>EVENT<|>MSUD refers to Maple Syrup Urine Disease, a metabolic disorder that affects the body's ability to process certain amino acids, leading to toxic buildup and requiring dietary management.)\n##\n(\"entity\"<|>BCAA<|>EVENT<|>BCAA stands for Branched-Chain Amino Acids, which are essential nutrients that the body obtains from proteins and are crucial for various metabolic processes.)\n##\n(\"entity\"<|>LEUCINA<|>PERSON<|>Leucina is an essential amino acid that plays a key role in protein synthesis and is particularly important in the context of metabolic disorders like MSUD.)\n##\n(\"entity\"<|>ISOLEUCINA<|>PERSON<|>Isoleucina is another essential amino acid that is important for muscle metabolism and is involved in the regulation of blood sugar levels.)\n##\n(\"entity\"<|>VALINA<|>PERSON<|>Valina is an essential amino acid that is important for muscle growth and tissue repair, and is also relevant in the context of metabolic disorders.)\n##\n(\"entity\"<|>NUTRICIÓN PARENTERAL<|>EVENT<|>Nutritional support provided intravenously, bypassing the usual process of eating and digestion, often used in patients with metabolic disorders.)\n##\n(\"entity\"<|>NUTRICIÓN ENTERAL<|>EVENT<|>Enteral nutrition refers to delivering nutrients directly to the stomach or intestine, often used for patients who cannot eat normally.)\n##\n(\"relationship\"<|>MSUD<|>BCAA<|>MSUD is a condition that affects the metabolism of BCAAs, leading to their toxic accumulation in the body<|>8)\n##\n(\"relationship\"<|>LEUCINA<|>MSUD<|>Leucina is one of the BCAAs that is particularly neurotoxic in the context of MSUD<|>7)\n##\n(\"relationship\"<|>ISOLEUCINA<|>MSUD<|>Isoleucina is another BCAA that is affected in MSUD, requiring dietary management<|>7)\n##\n(\"relationship\"<|>VALINA<|>MSUD<|>Valina is also a BCAA that is involved in the metabolic processes affected by MSUD<|>7)\n##\n(\"relationship\"<|>NUTRICIÓN PARENTERAL<|>MSUD<|>Nutritional support through parenteral means may be necessary for patients with MSUD to manage their amino acid levels<|>6)\n##\n(\"relationship\"<|>NUTRICIÓN ENTERAL<|>MSUD<|>Enteral nutrition is a method used to provide dietary support for patients with MSUD, ensuring they receive necessary nutrients<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: abor y la     mático deshidrogenasa), pero de forma práctica en la\nvariedad de la dieta para PKU y está suplementado con        clínica podemos distinguir la forma neonatal (se ma-\narginina, histidina, leucina, tirosina y triptófano para\ncomplementar el aporte proteico11, 12 . Los productos        nifiesta como un cuadro tóxico en el neonato), la for-\n\n                                                             ma intermedia (se presenta con fallo de medro y re-\nmás destacados son: harina, chocolate, puding, bebi-         traso psicomotor, ataxia y convulsiones) y la forma del\ndas deportivas, snacks.                                      adulto (sin clínica característica y que suele presentar-\n   Los GMP poseen otras propiedades como que presen-         se como crisis de ataxia, convulsiones y cetoacidosis\ntan una buena termoestabilidad y una adecuada solubi-        coincidiendo con procesos intercurrentes).\nlidad en ácidos. Otras de las propiedades de los GMP            El diagnóstico se realiza mediante determinación de aa\nson que podrían descender tanto la fenilalanina plasmá-      en sangre (presencia patognomónica y característica de\ntica como la cerebral y que disminuyen la sensación de       aloisoleucina) y se confirma con la determinación del dé-\nhambre a través de un descenso de la GHrelina8.              ficit enzimático en biopsia de piel y/o el estudio mutacional.\n---\n                                                  Tema 18.      Soporte nutricional en metabolopatías de los aminoácidos…                     311\n\n\n\n                         Leucina                                           Isoleucina                                          Valina\n\n\n\n                    Ác. α-isocaproico                            Ác. α-ceto-β-metilvalérico                           Ác. α-cetoisovalérico\n                                          Complejo multienzimático                          Complejo multienzimático\n                                           deshidrogenasa (MSUD)                             deshidrogenasa (MSUD)\n                       Isovaleril-CoA                                     α-metilbutiril-CoA                                Isobutiril-CoA\n\n\n\n                                       Isovaleril-CoA Deshidrogenasa(Acidemia isovalérica)\n\n\n\n     Acetoacetato                                   Acetil-CoA                                                             Propionil-CoA\n                                                                                                 Propionil-CoA carboxilasa(Acidemia propiónica)\n                                                                                                  Metilmalonil-CoA mutasa\n                                                                                                 (Acidemia metilmalónica)\n\n\n\n                                                                                                                             Succinil-CoA\n\n\n\nFigura 2.    Vías metabólicas de los aminoácidos ramificados y metabolopatías asociadas.\n\n\n\n3.2.    Tratamiento dietético en la fase aguda                                  Si la concentración plasmática de los BCAA descien-\n   Tiene como objetivo inducir el anabolismo y evitar el                      de por debajo de valores normales, sería necesario ini-\ncatabolismo proteico para conseguir disminuir las ci-                         ciar un suplemento (100-200 mg/día y 50-100 mg/día\nfras de los tres BCAA, en especial de la leucina, que es                      para valina e isoleucina, y leucina respectivamente).\nel más neurotóxico. Para ello, disponemos de varias                           3.3.   Tratamiento dietético en la fase\nposibilidades:                                                                       de mantenimiento\n   a.  Instaurar nutrición parenteral con una mezcla de                         El objetivo es mantener las siguientes concentracio-\n       aa exento de BCAA (no disponible en España) y                          nes de BCAA: leucina 100-300 μmol/l, isoleucina: 200-\n       un alto contenido energético con glucosa e insu-                       400 μmol/l y valina 200-400 μmol/l. Los aportes deben\n       lina si fuera necesario.                                               ser ajustados individualmente y basarse en las concen-\n   b. Instaurar nutrición enteral continua con una fór-                       traciones plasmáticas (tabla 4).\n       mula exenta de BCAA.                                                     En algunos casos debemos suplementar con isoleu-\n   c.  Nutrición enteral continua con una fórmula dilui-                      cina y valina si en el control bioquímico se detecta un\n       da y suplementada con polímeros de glucosa.                            descenso importante.\n\n\n\nTabla 4.    Requerimientos proteicos y energéticos en la MSUD según Wappner y Gibson16 .\n\n\n\n                                      Proteínas               Leucina               Isoleucina          Valina (mg/kg)             Kcal/kg\n                                        (g/kg)                (mg/kg)                (mg/kg)\n Recién nacidos                        2,5-3                   50-90                  20-50                  30-60                120-145\n Lactantes                               2-3                   40-80                  20-50                  30-60                115-145\n Escolares                             1,5-2                   20-40                   5-15                  10-30                  60-80\n Adolescentes y adultos                  1-1,2                  5-15                   5-15                  10-\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}